Expression, Epigenetic Patterns Predict Liver Cancer Response to Methylation-Inhibiting Drug

By assessing gene expression and DNA methylation patterns in liver cancer samples, a team of researchers from the National Cancer Institute has uncovered signatures to help predict sensitivity or resistance to the DNA methylation-inhibiting drug zebularine.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.